Kymab, Roche agree to evaluate KY1044, anti-PD-L1 immunotherapy in solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kymab Group Ltd. announced a clinical trial agreement with F. Hoffmann-La Roche Ltd.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login